AstraZeneca (AZN) Plans to Delist from Nasdaq and Directly List on NYSE in 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: seekingalpha
- Delisting Plan: AstraZeneca plans to delist its American Depositary Shares from Nasdaq after market close on January 30, 2026, and directly list its ordinary shares on the NYSE, indicating a strategic intent to harmonize its global market presence.
- Listing Timeline: The ordinary shares and debt securities are expected to commence trading on the NYSE from February 2, 2026, ensuring a smooth transition for investors to the new trading platform.
- Global Investor Strategy: This direct listing is part of AstraZeneca's shareholder-approved plan aimed at providing a unified listing structure for global investors, thereby enhancing the company's global profile and appeal.
- Nasdaq Replacement: Walmart will replace AstraZeneca in the Nasdaq 100 index effective January 20, 2026, reflecting a market reassessment of AstraZeneca's future strategy.
Analyst Views on AZN
Wall Street analysts forecast AZN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AZN is 102.75 USD with a low forecast of 95.00 USD and a high forecast of 108.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 93.990
Low
95.00
Averages
102.75
High
108.00
Current: 93.990
Low
95.00
Averages
102.75
High
108.00
About AZN
AstraZeneca PLC is a United Kingdom-based science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines. The Company operates across therapy areas, including Oncology; Cardiovascular, Renal and Metabolism (CVRM); Respiratory and Immunology (R&I); Vaccines and Immune Therapies (V&I), and Rare Disease. In the Oncology area, its key products include Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu. The key products of CVRM area include Farxiga/Forxiga, Brilinta/Brilique, Crestor, and Lokelma. In the R&I area, the key products are Symbicort, Fasenra, Breztri/Trixeo, and Tezspire. In the V&I Therapies area, the products are Beyfortus and FluMist. The products in the Rare Disease area are Ultomiris, Soliris, Strensiq, and Koselugo. It has about 191 projects in its development pipeline, including 19 new molecular entities (NMEs) in the late-stage pipeline. The Company distributes its products in over 125 countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
